BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 23515910)

  • 1. Correlation of p53 status with the response to chemotherapy-based treatment in esophageal cancer: a meta-analysis.
    Zhang SS; Huang QY; Yang H; Xie X; Luo KJ; Wen J; Cai XL; Yang F; Hu Y; Fu JH
    Ann Surg Oncol; 2013 Jul; 20(7):2419-27. PubMed ID: 23515910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    Kandioler D; Schoppmann SF; Zwrtek R; Kappel S; Wolf B; Mittlböck M; Kührer I; Hejna M; Pluschnig U; Ba-Ssalamah A; Wrba F; Zacherl J
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2280-6. PubMed ID: 25135238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus.
    Yamasaki M; Miyata H; Fujiwara Y; Takiguchi S; Nakajima K; Nishida T; Yasuda T; Matsuyama J; Mori M; Doki Y
    Ann Surg Oncol; 2010 Feb; 17(2):634-42. PubMed ID: 19941080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of p53 and p21 is useful for the prediction of preoperative chemotherapeutic effects in esophageal carcinoma.
    Nakashima S; Natsugoe S; Matsumoto M; Kijima F; Takebayashi Y; Okumura H; Shimada M; Nakano S; Kusano C; Baba M; Takao S; Aikou T
    Anticancer Res; 2000; 20(3B):1933-7. PubMed ID: 10928129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer.
    Mroz EA; Rocco JW
    J Clin Oncol; 2010 Feb; 28(5):715-7. PubMed ID: 20048171
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular factors and criteria for predicting the response to neoadjuvant treatment in patients with esophageal squamous cell carcinoma (ESCC) -- responder/non-responder.
    Predescu D; Gheorghe M; Boeriu M; Constantin A; Iosif C; Anghel R; Constantinoiu S
    Chirurgia (Bucur); 2012; 107(5):583-90. PubMed ID: 23116831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?
    Nason KS
    J Thorac Cardiovasc Surg; 2014 Nov; 148(5):2286-7. PubMed ID: 25444198
    [No Abstract]   [Full Text] [Related]  

  • 9. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Locati L; Quattrone P; Pierotti MA; Pilotti S; Licitra L
    J Clin Oncol; 2010 Feb; 28(5):761-6. PubMed ID: 20048189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multivariate analysis of the prognostic and predictive factors of response to concomitant radiochemotherapy in epidermoid cancers of the esophagus. Value of immunodetection of protein p53].
    Seitz JF; Perrier H; Monges G; Giovannini M; Gouvernet J
    Gastroenterol Clin Biol; 1995 May; 19(5):465-74. PubMed ID: 7589997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated mammalian target of rapamycin expression is associated with the response to chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Li SH; Huang EY; Lu HI; Huang WT; Yen CC; Huang WC; Chen CH
    J Thorac Cardiovasc Surg; 2012 Dec; 144(6):1352-9, 1359.e1. PubMed ID: 22841170
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer.
    Kitamura K; Saeki H; Kawaguchi H; Araki K; Ohno S; Kuwano H; Maehara Y; Sugimachi K
    Hepatogastroenterology; 2000; 47(32):419-23. PubMed ID: 10791203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
    Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
    Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive effect of p53 and p21 alteration on chemotherapy response and survival in locally advanced adenocarcinoma of the esophagus.
    Heeren PA; Kloppenberg FW; Hollema H; Mulder NH; Nap RE; Plukker JT
    Anticancer Res; 2004; 24(4):2579-83. PubMed ID: 15330218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors of the response to chemoradiotherapy in esophageal cancer.
    Ressiot E; Dahan L; Liprandi A; Giorgi R; Djourno XB; Padovani L; Alibert S; Ries P; Laquière A; Laugier R; Thomas P; Seitz JF
    Gastroenterol Clin Biol; 2008; 32(6-7):567-77. PubMed ID: 18555630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a correlation between molecular markers and response to neoadjuvant chemoradiotherapy in locally advanced squamous cell esophageal cancer?
    Arsenijevic T; Micev M; Nikolic V; Gavrilovic D; Radulovic S; Pesko P
    J BUON; 2012; 17(4):706-11. PubMed ID: 23335529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma.
    Miyazaki T; Kato H; Faried A; Sohda M; Nakajima M; Fukai Y; Masuda N; Manda R; Fukuchi M; Ojima H; Tsukada K; Kuwano H
    Anticancer Res; 2005; 25(4):2749-55. PubMed ID: 16080521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or the gastroesophageal junction: A meta-analysis based on clinical trials.
    Zhao X; Ren Y; Hu Y; Cui N; Wang X; Cui Y
    PLoS One; 2018; 13(8):e0202185. PubMed ID: 30138325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-3-3σ expression is associated with poor pathological complete response to neoadjuvant chemotherapy in human breast cancers.
    Nakamura Y; Oshima K; Naoi Y; Nakayama T; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Tamaki Y; Noguchi S
    Breast Cancer Res Treat; 2012 Jul; 134(1):229-36. PubMed ID: 22315133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microarray-based response prediction in esophageal adenocarcinoma.
    Schauer M; Janssen KP; Rimkus C; Raggi M; Feith M; Friess H; Theisen J
    Clin Cancer Res; 2010 Jan; 16(1):330-7. PubMed ID: 20028767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.